Evidence Level
Molybdenum research in supplement form is limited due to its rarity as a deficiency in free-living populations. The most critical clinical context involves molybdenum cofactor deficiency, an ultra-rare genetic disorder affecting approximately 1 in 100,000-200,000 individuals, which leads to severe neurological damage due to impaired sulfite metabolism (Schwahn et al., 2024). Supplementation studies have shown that molybdenum absorption from sodium molybdate exceeds 88% across various doses, with urinary excretion rapidly adjusting to maintain homeostasis (Turnlund et al., 1995). Interest in molybdenum for sulfite sensitivity primarily stems from case reports and functional medicine practices rather than randomized controlled trials.
Recent studies highlight the role of molybdenum in animal nutrition. A meta-analysis by Dias et al. (2013) found that dietary copper, molybdenum, and sulfur influence plasma copper levels in cattle, with higher copper-to-molybdenum ratios improving average daily gain. Additionally, a retrospective study of 1273 cows across 117 herds in Spain revealed that pasture-based, organic, and beef systems had higher rates of trace mineral deficiencies compared to conventional dairy herds (Fernández-Villa et al., 2025). These findings underscore the importance of balanced trace element supplementation in livestock.
In human nutrition, the ESPEN guideline by Berger et al. (2022) provides recommendations for assessing and prescribing micronutrients based on expert consensus due to limited interventional trial evidence. Similarly, Burjonrappa and Miller (2012) emphasized the need for individualized trace element dosing in parenteral nutrition for surgical neonates to prevent toxicity and ensure adequate metabolic support.
Overall, while molybdenum supplementation is not commonly required in human populations, its role in animal nutrition and rare genetic disorders highlights the need for further research and targeted clinical applications.